Table 1B.
Keypoints of the most relevant articles published in the last decade.
| Authors | Characteristics | Key points |
|---|---|---|
| Suh et al, 2012.42 | 38 patients with SP: 16 with SBP and 22 with SEP. | SBP patients more frequently progress to MM than SEP patients. Radiotherapy with doses ≥40 Gy demonstrates better LC in SBP. In the multivariate analysis, elevated β2-microglobulin is a significantly unfavorable prognostic factor affecting OS. |
| Hill et al, 2014.28 | OMD measured by MFC in 50 SBP patients. | Progression has been documented in 72% of patients with OMD vs 12.5% without. Monoclonal ULC are similarly predictive of outcome because progression has been documented in 91% vs 44% without. |
| Katodritou et al, 2014.43 | 97 patients with SP: 65 with SBP and 32 with SEP. | OS, MMFS, PFS and PFRS are better for SEP than SBP. In the multivariate analysis, prolonged PRFS and young age are positive predictors of OS. Achievement of CR is the only positive predictor of PRFS. Immunoparesis is the only negative predictor of progression to MM. The addition of chemotherapy or novel agent-based treatment increases toxicity without offering any survival advantage over radiotherapy. |
| Li et al, 2015.53 | 38 patients with SP: 16 with SBP and 22 with SEP. | Radiotherapy alone is associated with significantly higher 5-year LPFS, MFS, PFS and OS. |
| De Wall et al, 2016.18 | 76 patients with SP, 34% with SEP and 66% with SBP. | SBP patients have a higher risk of developing MM. No association could be shown between angiogenesis parameters and progression to MM. |
| Finsinger et al, 2016.27 | 53 patients with SP: 35 with SBP and 18 with SEP. | SBP patients have a significantly worse OS and PFS compared to SEP patients. On univariate analysis, bone disease and size (≥5 cm) impact negatively on PFS. Bone disease also affects OS. In multivariate analysis bone location is the only independent prognostic factor for PFS and OS. |
| Paiva et al, 2016.29 | OMD measured by MFC in 64 patients with SP: 35 with SBP and 29 with SEP. | Flow-positive SBP patients have significant higher risk to develop MM. No significant differences have been observed among SEP cases. |
| Thumallapally et al, 2017.10 | 1691 SP patients identified in the SEER database (1998–2007) | In univariate analysis the survival outcomes are better for younger male patients who receive radiotherapy with surgery. Patients who receive neoadjuvant radiotherapy have increased survival rates compared to those receiving adjuvant radiotherapy. The 5-year survival rates for patients with axial plasmacytoma are superior when radiotherapy is combined with surgery. In the multivariate analysis, age <60 years and treatment with either radiotherapy or surgery show superior survival rates. Age >60 years is associated with a lower 5-year survival in patients who progress to MM. |
SP: solitary plasmocytoma; SBP solitary bone plasmacytoma; SEP solitary extramedullary plasmacytoma; LC local control; MM multiple myeloma; Gy Gray; OS overall survival; PFS progression-free survival; MFS myeloma-free survival; OMD occult bone marrow disease; ULC urinary light chains; PFRS plasmacytoma relapse-free survival; LPFS local progression-free survival; MFC multiparameter flow cytometry; SEER Surveillance, Epidemiology and End Results.